These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24471188)

  • 21. [PIK3CA gene mutations in Chinese women with HR
    Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
    Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.
    Liang X; Lau QC; Salto-Tellez M; Putti TC; Loh M; Sukumar S
    Cancer Biol Ther; 2006 May; 5(5):544-8. PubMed ID: 16582596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
    Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiating breast cancer by PIK3CA mutation.
    Miller TW
    Breast Cancer Res; 2012 Feb; 14(1):301. PubMed ID: 22315990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
    Pérez-Tenorio G; Alkhori L; Olsson B; Waltersson MA; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
    Clin Cancer Res; 2007 Jun; 13(12):3577-84. PubMed ID: 17575221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
    Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
    Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
    Lerma E; Catasus L; Gallardo A; Peiro G; Alonso C; Aranda I; Barnadas A; Prat J
    Virchows Arch; 2008 Aug; 453(2):133-9. PubMed ID: 18679714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
    Azizi Tabesh G; Izadi P; Fereidooni F; Emami Razavi AN; Tavakkoly Bazzaz J
    Cancer Invest; 2017 Jan; 35(1):36-42. PubMed ID: 27901576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
    Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
    Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
    Dumont AG; Dumont SN; Trent JC
    Chin J Cancer; 2012 Jul; 31(7):327-34. PubMed ID: 22640628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
    Arsenic R; Treue D; Lehmann A; Hummel M; Dietel M; Denkert C; Budczies J
    BMC Clin Pathol; 2015; 15():20. PubMed ID: 26587011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.
    Michelucci A; Di Cristofano C; Lami A; Collecchi P; Caligo A; Decarli N; Leopizzi M; Aretini P; Bertacca G; Porta RP; Ricci S; Della Rocca C; Stanta G; Bevilacqua G; Cavazzana A
    Diagn Mol Pathol; 2009 Dec; 18(4):200-5. PubMed ID: 19861897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
    Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
    Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.